We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+13.07%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$174M
AUM Growth
+$60M
Cap. Flow
+$42M
Cap. Flow %
24.17%
Top 10 Hldgs %
68.58%
Holding
37
New
14
Increased
5
Reduced
10
Closed
7

Top Buys

1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$23.7M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$18.2M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$8.85M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$5.46M
5
XOMA
Xoma
XOMA
+$3.11M

Top Sells

1
BSTC
BioSpecifics Technologies Corp.
BSTC
+$13.2M
2
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$11.2M
3
AMRN
Amarin Corp
AMRN
+$2.77M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$2.11M
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$1.82M

Sector Composition

1 Healthcare 92.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
1
Vanda Pharmaceuticals
VNDA
$327M
$23.2M 13.34%
1,260,288
+1,039,440
+471% +$23.7M
AMRN
2
Amarin Corp
AMRN
$292M
$19.6M 11.3%
47,319
-7,681
-14% -$2.77M
LGND icon
3
Ligand Pharmaceuticals
LGND
$6.08B
$18.9M 10.85%
+240,450
New +$18.2M
NEOS
4
DELISTED
Neos Therapeutics, Inc
NEOS
$11.8M 6.77%
4,511,504
+301,351
+7% +$707K
APEN
5
DELISTED
Apollo Endosurgery, Inc.
APEN
$9.65M 5.55%
2,580,518
+395,092
+18% +$1.38M
BDSI
6
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$8.16M 4.69%
1,539,437
-2,442,430
-61% -$11.2M
HTGM
7
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$7.09M 4.08%
15,754
+888
+6% +$389K
ADMS
8
DELISTED
Adamas Pharmaceuticals
ADMS
$7M 4.03%
+984,329
New +$8.85M
CPIX icon
9
Cumberland Pharmaceuticals
CPIX
$102M
$6.98M 4.02%
1,201,975
-111,454
-8% -$646K
ALIM
10
DELISTED
Alimera Sciences
ALIM
$6.87M 3.95%
432,241
-4,277
-1% -$65.1K
ENTA icon
11
Enanta Pharmaceuticals
ENTA
$400M
$5.81M 3.34%
+60,840
New +$5.46M
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.75M 3.31%
4,074,944
+2,643
+0.1% +$3.7K
CTIC
13
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.88M 2.23%
4,000,000
-1,726,579
-30% -$1.82M
OPNT
14
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$3.87M 2.23%
294,894
-63,066
-18% -$919K
APVO icon
15
Aptevo Therapeutics
APVO
$5.91M
– –
0
– –
VIVE
16
DELISTED
VIVEVE MED INC
VIVE
$3.2M 1.84%
3,403
-15
-0.4% -$15.9K
XOMA
17
DELISTED
Xoma
XOMA
$2.82M 1.62%
+227,430
New +$3.11M
FOMX
18
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.74M 1.57%
730,004
-563,173
-44% -$2.11M
EBS icon
19
Emergent Biosolutions
EBS
$394M
$2.36M 1.36%
+46,800
New +$2.76M
OXFD
20
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.19M 1.26%
127,224
-95,097
-43% -$1.5M
MTNB icon
21
Matinas BioPharma
MTNB
$2.2M
$2.19M 1.26%
+40,160
New +$2.16M
AFMD
22
DELISTED
Affimed
AFMD
$2.12M 1.22%
50,574
-20,834
-29% -$749K
CHMA
23
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.56M 0.9%
+300,000
New +$1.32M
VSTM icon
24
Verastem
VSTM
$530M
$1.48M 0.85%
+41,667
New +$1.65M
IDXG
25
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$1.15M 0.66%
+143,403
New +$1.35M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Stonepine Capital Management held 37 positions worth $174M, up 53% from $114M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Stonepine Capital Management deployed $42M of net new capital in Q1 2019, opening 14 new positions and adding to 5 existing holdings. Its largest new stake was Ligand Pharmaceuticals: 240,450 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was BioDelivery Sciences International, Inc., an estimated $11.2M trimmed.

  • Stonepine Capital Management's largest Q1 2019 buy was Ligand Pharmaceuticals: 240,450 shares worth $18.9M.
  • Stonepine Capital Management added most to Vanda Pharmaceuticals in Q1 2019, an estimated $23.7M increase.
  • Stonepine Capital Management's biggest Q1 2019 reduction was BioDelivery Sciences International, Inc., cutting an estimated $11.2M.
  • Stonepine Capital Management fully exited BioSpecifics Technologies Corp. in Q1 2019, selling an estimated $13.2M.
  • Stonepine Capital Management's ten largest holdings make up 69% of its $174M portfolio in Q1 2019.
  • Stonepine Capital Management opened 14 new positions and closed 7 in Q1 2019.
  • Stonepine Capital Management's portfolio value rose 53% quarter-over-quarter to $174M.

Based on Stonepine Capital Management's 13F filing for Q1 2019, filed 14 May 2019.